Improvement of apathy in early Parkinson’s disease

Apathy is a disabling symptom in Parkinson's disease (PD). The effect of dopaminergic treatment on apathy is inconsistent, depending on the stage of the disease, the type of apathy and strongly influenced by placebo effect. Our study assessed the evolution of a cohort of 86 de novo, drug naive PD patients for 4 years, after dopaminergic treatment introduction. The main objective of the study was the change of apathy from baseline to follow-up and secondary outcomes were the change of other neuropsychiatric symptoms. At 4 years there was an improvement of apathy (p = 0.002), mainly driven by improvement of baseline apathy (p = 0.001). This was associated with an improvement of anxiety (p = 0.001), an increase in hyperdopaminergic behavior including nocturnal hyperactivity with consecutive diurnal sleepiness (p = 0.001 and p < 0.001), independently of the presence of apathy at baseline. These findings confirm, in a large real-life cohort, that dopaminergic treatment improves motivational apathy in early PD.

Authors

Institutions

Publication Details

Journal
npj Parkinson s Disease
Published
2025-04-24
DOI
https://doi.org/10.1038/s41531-025-00937-w
Citations
1
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
1.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Improvement of apathy in early Parkinson’s disease

Emmanuelle Schmitt, Paul Krack, Valérie Fraix, Sara Meoni et al.
1 citations
npj Parkinson s Disease
Parkinson's Disease Mechanisms and Treatments
1.39
article

Improvement of apathy in early Parkinson’s disease

Emmanuelle Schmitt, Paul Krack, Valérie Fraix, Sara Meoni, Christine Tranchant, Stéphane Thobois, Anna Castrioto, Hélène Klinger, E Moro, Amélie Bichon, Eugénie Lhommée, Mathieu Anheim, Pierre Pélissier, D Sourd
article en
1 citations

Abstract

Apathy is a disabling symptom in Parkinson's disease (PD). The effect of dopaminergic treatment on apathy is inconsistent, depending on the stage of the disease, the type of apathy and strongly influenced by placebo effect. Our study assessed the evolution of a cohort of 86 de novo, drug naive PD patients for 4 years, after dopaminergic treatment introduction. The main objective of the study was the change of apathy from baseline to follow-up and secondary outcomes were the change of other neuropsychiatric symptoms. At 4 years there was an improvement of apathy (p = 0.002), mainly driven by improvement of baseline apathy (p = 0.001). This was associated with an improvement of anxiety (p = 0.001), an increase in hyperdopaminergic behavior including nocturnal hyperactivity with consecutive diurnal sleepiness (p = 0.001 and p < 0.001), independently of the presence of apathy at baseline. These findings confirm, in a large real-life cohort, that dopaminergic treatment improves motivational apathy in early PD.

npj Parkinson s DiseaseVol. 11(1)
Université Claude Bernard Lyon 1 (FR), Centre National de la Recherche Scientifique (FR), Inserm (FR), Centre Hospitalier Universitaire de Grenoble (FR), University Hospital of Bern (CH), Institut de génétique et de biologie moléculaire et cellulaire (FR), Centre de Recherche en Neurosciences de Lyon (FR), Laboratoire de Psychologie et NeuroCognition (FR), Hôpital Pierre Wertheimer (FR), Hôpital Louis Pradel (FR), Hôpitaux Universitaires de Strasbourg (FR), Grenoble Institute of Neurosciences (FR), Université de Strasbourg (FR), Université Grenoble Alpes (FR)
Parkinson Vereniging
Zero hunger
Openalex Percentile: Top 21%
Parkinson's Disease Mechanisms and Treatments
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.